Cargando…
A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
BACKGROUND: Although the aggregate of data among patients with multiple sclerosis (MS) have shown similar efficacy between dimethyl fumarate (DMF) and fingolimod (FTY), most studies have not assessed long-term worsening of disability. We compared long-term disability worsening over 5 years, as asses...
Autores principales: | Salter, Amber, Lancia, Samantha, Cutter, Gary, Marrie, Ruth Ann, Mendoza, Jason P., Lewin, James B., Fox Mellen, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252399/ https://www.ncbi.nlm.nih.gov/pubmed/34262613 http://dx.doi.org/10.1177/17562864211021177 |
Ejemplares similares
-
Erratum to “A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod”
Publicado: (2021) -
Severity and worsening of fatigue among individuals with multiple sclerosis
por: Salter, Amber, et al.
Publicado: (2023) -
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018) -
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018) -
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)